20 January 2022 5 Min Read
Omicron vaccine is all well and good, but the real money is on an all-in-one jab
Researchers look for alternative strategy as variant-specific vaccines seem doomed to play perpetual catch-up
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In